COVID-19 Vaccination Rates in a Global HIV Cohort

J Infect Dis. 2022 Feb 15;225(4):603-607. doi: 10.1093/infdis/jiab575.

Abstract

Little is known regarding coronavirus disease 2019 (COVID-19) vaccination rates in people with HIV (PWH), a vulnerable population with significant morbidity from COVID-19. We assessed COVID-19 vaccination rates among 6952 PWH in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) compared to region- and country-specific vaccination data. The global probability of COVID-19 vaccination through end of July 2021 was 55% among REPRIEVE participants with rates varying substantially by Global Burden of Disease (GBD) superregion. Among PWH, factors associated with COVID-19 vaccination included residence in high-income regions, age, white race, male sex, body mass index, and higher cardiovascular risk. Clinical Trials Registration. NCT02344290.

Keywords: COVID-19; Global Burden of Disease region; human immunodeficiency virus; vaccination.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19 Vaccines / administration & dosage*
  • COVID-19* / prevention & control
  • HIV Infections* / therapy
  • Humans
  • Male
  • Randomized Controlled Trials as Topic
  • Vaccination / statistics & numerical data*

Substances

  • COVID-19 Vaccines

Associated data

  • ClinicalTrials.gov/NCT02344290